David Lubner is an experienced financial professional with tenure in the biotech and pharmaceutical industry. He serves as executive vice president and chief financial officer of Ra Pharma, acquired by UCB in April 2020.
Prior to joining Ra Pharma, David served as a member of the senior management team of Tetraphase Pharmaceuticals, Inc. and PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company, which was acquired by IMS Health in 2015. In addition he served as a senior leader at ProScript, Inc., where Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer multiple myeloma, was discovered. He currently serves on the board of Dyne Therapeutics and previously served on the Board of Directors of Nightstar Therapeutics plc (Nasdaq: NITE), a company focused on the development of one-time retinal gene therapies for patients suffering from rare inherited retinal diseases, which was acquired by Biogen in June 2019.
David is a Certified Public Accountant. He received his B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University.